Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.
Aptar COO Steve Hagge on how the firm's close client relationships and FDA-approved dispensers give the firm an advantage in consumer packaging.
Five stats from the market and the stories behind them. This week: a steep 41% dividend cut, a surprising 12% sales gain, and more.
©2012 Morningstar Advisor. All right reserved.